NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy.

康涅狄格州纽黑文和纽约，2025年3月11日（GLOBE NEWSWIRE）-- Arvinas, Inc.（纳斯达克代码：ARVN）与辉瑞公司（纽约证券交易所代码：PFE）今天宣布了3期VERITAC-2临床试验（NCT05654623）的积极顶线结果。该试验评估了vepdegestrant单药疗法对比氟维司群在雌激素受体阳性、人表皮生长因子受体2阴性（ER+/HER2-）晚期或转移性乳腺癌成人患者中的疗效，这些患者的疾病在接受细胞周期蛋白依赖性激酶（CDK）4/6抑制剂和内分泌治疗后出现进展。

These are the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) ER degrader..

这些是vepdegestrant的首批关键数据，vepdegestrant是一种潜在的首创研究性口服PROteolysis TArgeting Chimera (PROTAC) ER降解剂。

The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant. The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population.

该试验在雌激素受体1突变（ESR1m）人群中达到了主要终点，与氟维司群相比，无进展生存期（PFS）显示出具有统计学意义和临床意义的改善。结果超过了ESR1m人群中预设的目标风险比0.60。

The trial did not reach statistical significance in improvement in PFS in the intent-to-treat (ITT) population..

在意向治疗（ITT）人群中，试验未达到统计学显著性改善无进展生存期（PFS）。

“The first Phase 3 data readout for a PROTAC degrader represents a significant achievement and these data show that vepdegestrant has the potential to provide clinically meaningful outcomes for thousands of patients with metastatic breast cancer whose tumors harbor estrogen receptor 1 mutations,” said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas.

“首个PROTAC降解剂的三期临床数据读出代表了一项重大成就，这些数据显示vepdegestrant有潜力为成千上万名携带雌激素受体1突变的转移性乳腺癌患者提供具有临床意义的结果，”Arvinas公司董事长、首席执行官兼总裁John Houston博士说道。

“We want to thank the patients and investigators who participated in this trial, and we look forward to sharing these data with health authorities as well as at a medical conference in 2025.”.

“我们要感谢参与这项试验的患者和研究人员，我们期待着在2025年的医学会议上与卫生当局分享这些数据。”

Overall survival was not mature at the time of the analysis, with less than a quarter of the required number of events having occurred. The trial will continue to assess overall survival as a key secondary endpoint. In the trial, vepdegestrant was generally well tolerated and its safety profile was consistent with what has been observed in previous studies.

在分析时，总生存期数据尚未成熟，发生的关键事件数量不到四分之一。试验将继续评估总生存期作为关键的次要终点。在试验中，vepdegestrant 通常具有良好的耐受性，其安全性与之前研究中观察到的结果一致。

Detailed results from VERITAC-2 will be submitted for presentation at a medical meeting later this year, and these data will be shared with global regulatory authorities to potentially support regulatory filings..

VERITAC-2 的详细结果将在今年晚些时候提交给医学会议展示，并且这些数据将与全球监管机构分享，以可能支持监管文件的提交。

“Patients with advanced ER+/HER2- metastatic breast cancer face significant clinical challenges, with limited treatment options following disease progression and the development of resistance to available endocrine therapies,” said Megan O’Meara, M.D., Interim Chief Development Officer, Pfizer Oncology.

“患有晚期ER+/HER2-转移性乳腺癌的患者面临着重大的临床挑战，在疾病进展和对现有内分泌治疗产生耐药性后，治疗选择非常有限，”辉瑞肿瘤学临时首席开发官梅根·奥米拉医学博士表示。

“These data from VERITAC-2 support the potential of vepdegestrant to give patients whose tumors harbor ESR1 mutations additional time without disease progression, compared to fulvestrant.”.

“VERITAC-2 的这些数据支持了 vepdegestrant 相较于 fulvestrant，有可能为携带 ESR1 突变的肿瘤患者提供更长的无疾病进展时间。”

Vepdegestrant is an investigational oral PROTAC ER degrader for ER+/HER2- breast cancer being jointly developed by Arvinas and Pfizer and is designed to harness the body’s natural protein disposal system to specifically target and degrade the ER. In February 2024, the companies announced that the U.S.

Vepdegestrant 是一种研究性的口服 PROTAC ER 降解剂，用于治疗 ER+/HER2- 乳腺癌，由 Arvinas 和辉瑞公司共同开发，旨在利用人体天然的蛋白质处理系统来特异性靶向并降解 ER。2024 年 2 月，这些公司宣布美国。

Food and Drug Administration (FDA) granted Fast Track designation for the investigation of vepdegestrant for monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy..

美国食品药品监督管理局（FDA）授予vepdegestrant快速通道资格，用于研究该药物在既往接受过内分泌治疗的ER+/HER2-晚期或转移性乳腺癌成人患者中的单药治疗效果。

About Metastatic Breast Cancer

关于转移性乳腺癌

About 2.3 million new breast cancer diagnoses were reported globally in 2022,

2022年全球报告了大约230万例新的乳腺癌诊断，

1

1

and it is estimated there will be nearly 320,000 people diagnosed with breast cancer in the U.S. in 2025.

据估计，2025 年美国将有近 32 万人被诊断出患有乳腺癌。

2

2

Estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer accounts for approximately 70% of all cases.

雌激素受体阳性、人表皮生长因子受体2阴性（ER+/HER2-）乳腺癌约占所有病例的70%。

3

3

Nearly 30% of women initially diagnosed with early-stage breast cancer will ultimately develop metastatic breast cancer (MBC),

最初诊断为早期乳腺癌的女性中，近30%最终会发展为转移性乳腺癌 (MBC)，

4

4

the most advanced stage in which the disease has spread beyond the breast to other parts of the body. Treatment advances have helped those with MBC better manage symptoms, slow tumor growth, and may allow them to live longer, but most patients ultimately develop resistance to current standard-of-care treatments in the first-line setting and experience disease progression.

最晚期阶段，疾病已经扩散到乳房以外的身体其他部位。治疗的进步帮助患有MBC的人更好地管理症状、减缓肿瘤生长，并可能延长他们的生命，但大多数患者最终会对当前一线标准治疗产生抗药性，并经历疾病进展。

ESR1 mutations are a common cause of acquired resistance and are found in approximately 40% of patients in the second-line setting..

ESR1突变是获得性耐药的常见原因，在二线治疗中约40%的患者中可发现。

5

5

6

6

7

7

About the VERITAC-2 Clinical Trial

关于VERITAC-2临床试验

The Phase 3 VERITAC-2 clinical trial (NCT05654623) is a global randomized study evaluating the efficacy and safety of vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The trial enrolled 624 patients at sites in 26 countries who had previously received treatment with a CDK4/6 inhibitor plus endocrine therapy..

第3期VERITAC-2临床试验（NCT05654623）是一项全球随机研究，评估了vepdegestrant（ARV-471）单药治疗与氟维司群在ER+/HER2-晚期或转移性乳腺癌患者中的疗效和安全性。该试验在26个国家的试验点招募了624名先前曾接受过CDK4/6抑制剂加内分泌治疗的患者。

Patients were randomized to receive either vepdegestrant once daily, orally on a 28-day continuous dosing schedule, or fulvestrant, administered intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each 28-day cycle starting from Day 1 of Cycle 2. The primary endpoint was progression-free survival (PFS) in the intent-to-treat and ESR1m populations as determined by blinded independent central review.

患者被随机分配接受维佩地司特每日一次口服，连续28天给药方案，或氟维司群，在第1周期的第1天和第15天以及从第2周期第1天开始的每个28天周期的第1天肌肉注射。主要终点是由盲态独立中心审查确定的意向治疗人群和ESR1m人群的无进展生存期（PFS）。

Overall survival is a key secondary endpoint..

总体生存率是一个关键的次要终点。

About Vepdegestrant

关于Vepdegestrant

Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) breast cancer.

Vepdegestrant 是一种研究性、口服生物可利用的 PROTAC（蛋白水解靶向嵌合体）蛋白降解剂，旨在特异性靶向并降解雌激素受体 (ER)，用于治疗 ER 阳性 (ER+)/人表皮生长因子受体 2 (HER2) 阴性 (ER+/HER2-) 的乳腺癌患者。

Vepdegestrant is being developed as a potential monotherapy and as part of combination therapy across multiple treatment settings for ER+/HER2- metastatic breast cancer..

Vepdegestrant 正在被开发为一种潜在的单药疗法，并作为组合疗法的一部分，用于治疗 ER+/HER2- 转移性乳腺癌的多种治疗环境。

In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits.

2021年7月，Arvinas宣布与辉瑞达成全球合作，共同开发和商业化vepdegestrant；Arvinas和辉瑞将分担全球开发成本、商业化费用和利润。

The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy.

美国食品药品监督管理局（FDA）已授予vepdegestrant快速通道资格，用于治疗既往接受过内分泌治疗的ER+/HER2-晚期或转移性乳腺癌成人患者。

About Arvinas

关于Arvinas

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

Arvinas（纳斯达克股票代码：ARVN）是一家处于临床阶段的生物技术公司，致力于改善那些受衰弱性和危及生命疾病的患者的生活。通过其PROTAC（蛋白水解靶向嵌合体）蛋白降解平台，该公司正在引领蛋白降解疗法的开发，旨在利用人体天然的蛋白质处理系统，选择性且高效地降解并清除致病蛋白。

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders.

Arvinas目前正在通过临床开发项目推进多种研究性药物，包括针对局部晚期或转移性ER+/HER2-乳腺癌患者的雌激素受体的vepdegestrant；针对复发/难治性非霍奇金淋巴瘤的BCL6靶向药物ARV-393；以及针对神经退行性疾病的LRRK2靶向药物ARV-102。

Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X..

Arvinas 总部位于康涅狄格州纽黑文。如需更多关于 Arvinas 的信息，请访问 www.arvinas.com，并在 LinkedIn 和 X 上关注我们。

About Pfizer Oncology

辉瑞肿瘤学概况

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics.

在辉瑞肿瘤学，我们正处于癌症治疗新时代的前沿。我们行业领先的资产组合和广泛的管线包括三种核心作用机制，从多个角度攻击癌症，包括小分子、抗体药物偶联物 (ADC)、双特异性抗体，以及其他免疫肿瘤学生物制剂。

We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives..

我们专注于在一些全球最常见的癌症中提供变革性的治疗方法，包括乳腺癌、泌尿生殖系统癌症、血液肿瘤学以及胸部癌症（包括肺癌）。在科学的驱动下，我们致力于加速突破，帮助癌症患者过上更好、更长寿的生活。

About Pfizer: Breakthroughs That Change Patients’ Lives

关于辉瑞：改变患者生活的突破性进展

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

在辉瑞，我们运用科学和全球资源为人们带来延长和显著改善他们生活的疗法。我们努力在医疗保健产品的发现、开发和生产过程中树立质量、安全和价值的标准，包括创新药物和疫苗。

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

每天，辉瑞的同事们在发达市场和新兴市场开展工作，推动健康、预防、治疗和攻克当今最令人恐惧的疾病。作为全球首屈一指的创新型生物制药公司之一，我们与医疗保健提供者、政府和当地社区合作，支持并扩大全球获得可靠且负担得起的医疗保健的机会。

For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on X at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer..

175年来，我们一直努力为我们所服务的每个人带来改变。我们经常在www.pfizer.com网站上发布可能对投资者重要的信息。此外，欲了解更多信息，请访问我们的网站www.pfizer.com，并在X上关注我们@Pfizer和@Pfizer_News，以及LinkedIn、YouTube，并在Facebook上点赞我们的页面Facebook.com/Pfizer。

Arvinas Forward-Looking Statements

阿维纳斯前瞻性声明

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: vepdegestrant having the potential to provide clinically meaningful outcomes for thousands of patients with metastatic breast cancer whose tumors harbor estrogen receptor 1 mutations; Arvinas’ and Pfizer’s plans to share data from the Phase 3 VERITAC-2 clinical trial with health authorities, including to potentially support regulatory filings, as well as at a medical conference in 2025; and vepdegestrant’s development as a potential monotherapy and as part of combination therapy across multiple treatment settings for estrogen receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer.

本新闻稿包含《1995年私人证券诉讼改革法案》所指的前瞻性声明，涉及重大风险和不确定性，包括以下声明：vepdegestrant有望为数千名携带雌激素受体1突变的转移性乳腺癌患者提供具有临床意义的结果；Arvinas和辉瑞计划在2025年向卫生当局分享第三阶段VERITAC-2临床试验的数据，可能用于支持监管文件提交，并在医学会议上展示；以及vepdegestrant作为潜在单药疗法及联合疗法的一部分，在多种治疗环境中针对雌激素受体阳性、人类表皮生长因子受体2阴性的转移性乳腺癌的开发进展。

All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “target,” “goal,” “potential,” “will,” “would,” “could,” “should,” “look forward,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words..

本新闻稿中包含的所有声明，除历史事实声明外，包括有关Arvinas的战略、未来运营、未来财务状况、未来收入、预计成本、前景、计划和管理层目标的声明，均为前瞻性声明。词语“预期”、“相信”、“估计”、“预计”、“意图”、“可能”、“计划”、“目标”、“潜力”、“将”、“可能”、“能够”、“应该”、“期待”、“继续”及类似表达旨在识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词语。

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between Arvinas and Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant as a monotherapy and as part of combination therapy; whether Arvinas will be able to successfully conduct and complete development for its other product candidates, including ARV-393 and ARV-102; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S.

Arvinas可能实际上无法实现这些前瞻性陈述中披露的计划、意图或预期，您不应过度依赖此类前瞻性陈述。由于各种风险和不确定性，实际结果或事件可能与Arvinas所作出的前瞻性陈述中披露的计划、意图和预期存在重大差异，这些风险和不确定性包括但不限于：Arvinas与辉瑞是否能够成功履行双方在合作中的各自义务；Arvinas与辉瑞是否能够成功进行并完成vepdegestrant作为单药疗法及联合疗法的临床开发；Arvinas是否能够成功进行并完成其其他候选产品的开发，包括ARV-393和ARV-102；Arvinas与辉瑞是否能够按当前时间表或根本获得vepdegestrant及其他候选产品的上市批准并将其商业化；Arvinas保护其知识产权组合的能力；Arvinas对第三方的依赖；Arvinas是否能够在需要时筹集资金；Arvinas的现金及现金等价物资源是否足以满足其可预见及不可预见的运营费用和资本支出需求；以及Arvinas截至2024年12月31日年度的Form 10-K年报中“风险因素”部分及其他随后提交给美国证券交易委员会的报告中讨论的其他重要因素。

Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-lookin.

证券交易委员会。本新闻稿中包含的前瞻性陈述反映了Arvinas对未来事件的当前看法，Arvinas不承担更新任何前瞻性陈述的义务。

Pfizer Disclosure Notice:

辉瑞披露声明：

The information contained in this release is as of March 11, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

本新闻稿中的信息截至2025年3月11日。辉瑞不对因新信息、未来事件或发展而更新本新闻稿中包含的前瞻性声明承担任何责任。

This release contains forward-looking information about Pfizer Oncology and vepdegestrant, including its potential benefits, vepdegestrant’s potential for adults with ER+/HER2- advanced or metastatic breast cancer whose disease progressed following prior treatment with CDK 4/6 inhibitors and endocrine-based therapy and plans to share these data with global regulatory authorities to potentially support regulatory filings, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements..

本发布包含有关辉瑞肿瘤学和vepdegestrant的前瞻性信息，包括其潜在益处、vepdegestrant针对先前接受过CDK 4/6抑制剂和内分泌治疗后疾病进展的ER+/HER2-晚期或转移性乳腺癌成人患者的潜力，以及计划与全球监管机构分享这些数据以可能支持监管文件提交等内容，涉及重大风险和不确定性，可能导致实际结果与此类声明中明示或暗示的结果存在重大差异。

Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; whether the VERITAC-2 trial will meet the secondary endpoint for overall survival; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any jurisdictions for any potential indication for vepdegestrant; whether and when any such applications that may be filed for vepdegestrant may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy, and, if approved, whether vepdegestrant will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of vepdegestrant; whether the collaboration between Pfizer and Arvinas will be successful; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; and competitive developments..

风险和不确定性包括但不限于研发中固有的不确定性，包括能否达到预期的临床终点、我们临床试验的启动和/或完成日期、监管提交日期、监管批准日期和/或上市日期，以及可能出现不利的新临床数据和对现有临床数据的进一步分析；VERITAC-2 试验是否将达到总生存期的次要终点；临床试验数据可能受到监管机构不同解释和评估的风险；监管机构是否会对我们的临床研究设计和结果感到满意；在任何司法管辖区，针对 vepdegestrant 的任何潜在适应症，药物申请是否及何时可能提交；任何此类针对 vepdegestrant 提交的申请是否及何时可能获得监管机构的批准，这将取决于众多因素，包括确定产品的益处是否超过其已知风险，以及确定产品的疗效，并且如果获得批准，vepdegestrant 是否会在商业上取得成功；监管机构关于标签、生产工艺、安全性和/或其他可能影响 vepdegestrant 可用性或商业潜力的事项的决定；辉瑞与 Arvinas 之间的合作是否会成功；新冠疫情对我们业务、运营和财务结果的影响的不确定性；以及竞争发展。

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S.

辉瑞公司在截至2024年12月31日的财政年度的Form 10-K年度报告及其后续的Form 10-Q报告中，特别是在标题为“风险因素”和“前瞻性信息及可能影响未来结果的因素”的章节中，以及其后续的Form 8-K报告中，均可找到对风险和不确定性的进一步描述，所有这些报告均已提交给美国证券交易委员会。

Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com..

证券交易委员会，并可在www.sec.gov和www.pfizer.com获取。

1

1

World Health Organization. (2024, March 13).

世界卫生组织。（2024年3月13日）

Breast cancer

乳腺癌

. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/breast-cancer

世界卫生组织。https://www.who.int/news-room/fact-sheets/detail/breast-cancer

2

2

Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025 Jan-Feb;75(1):10-45. doi: 10.3322/caac.21871. Epub 2025 Jan 16. PMID: 39817679; PMCID: PMC11745215.

西格尔 RL，克拉茨 TB，贾昆托 AN，宋 H，杰马尔 A。2025年癌症统计。《CA：临床肿瘤学杂志》。2025年1-2月；75(1):10-45。doi: 10.3322/caac.21871。电子版发表于2025年1月16日。PMID: 39817679；PMCID: PMC11745215。

3

3

Surveillance, Epidemiology, and End Results Program Data,

监测、流行病学和最终结果项目数据，

https://seer.cancer.gov/statfacts/html/breast-subtypes.html

https://seer.cancer.gov/statfacts/html/breast-subtypes.html

.

。

4

4

Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis.

雷迪格 AJ，麦克阿利斯特 SS。乳腺癌作为一种系统性疾病：转移的观点。

J Intern Med

内科杂志

. 2013;274(2):113-126. doi:10.1111/joim.12084.

. 2013;274(2):113-126. doi:10.1111/joim.12084.

5

5

Bidard F-C, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of Clinical Onoclogy. 2022 May .

Bidard F-C 等。Elacestrant（口服选择性雌激素受体降解剂）与标准内分泌治疗用于雌激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌：来自随机III期EMERALD试验的结果。《临床肿瘤学杂志》。2022年5月。

https://doi.org/10.1200/JCO.22.00338

https://doi.org/10.1200/JCO.22.00338

.

。

6

6

Kalinsky, K. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. Journal of Clinical Oncology. 2024 Dec.

Kalinsky, K. 阿贝马西利布联合氟维司群在CDK4/6抑制剂治疗进展后的晚期乳腺癌中的应用：来自III期postMONARCH试验的结果。《临床肿瘤学杂志》。2024年12月。

https://doi.org/10.1200/JCO-24-0208

https://doi.org/10.1200/JCO-24-0208

.

。

7

7

Tolaney, S. et al. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer. Journal of Clinical Oncology.

Tolaney, S. 等。AMEERA-3：Amcenestrant（口服选择性雌激素受体降解剂）与标准内分泌单药治疗在雌激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌中的随机二期研究。《临床肿瘤学杂志》。

https://ascopubs.org/doi/full/10.1200/JCO.22.02746

https://ascopubs.org/doi/full/10.1200/JCO.22.02746

.

。

Source: Arvinas, Inc.

来源：Arvinas公司

Whatever your topic of interest,

无论你感兴趣的话题是什么，

subscribe to our newsletters

订阅我们的新闻通讯

to get the best of Drugs.com in your inbox.

获取 Drugs.com 的最佳资讯到您的收件箱。